How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients

The FDA Commissioner's new National Priority Voucher program seeks to accelerate drug approvals for products meeting certain criteria. Interestingly, the program intends to increase affordability of new drugs. With few specifics available as to how the program will achieve that goal, this paper proposes a framework for leveraging independent value assessments to achieve affordable access while incentivizing evidence development and innovation.